UBS AM’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

UBS AM’s Portfolio FMTX Stock Details FMTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-18,528	Closed	-$370K	–	2810
2022 Q3	$370K	Buy	18,528 +4,228	+30%	+$55.8K	﹤0.01%	2442
2022 Q2	$98.5K	Hold	14,300	–	–	﹤0.01%	2651
2022 Q1	$133K	Hold	14,300	–	–	﹤0.01%	2717
2021 Q4	$203K	Hold	14,300	–	–	﹤0.01%	2758
2021 Q3	$332K	Hold	14,300	–	–	﹤0.01%	2599
2021 Q2	$356K	Buy	14,300 +3,400	+31%	+$91.4K	﹤0.01%	2611
2021 Q1	$305K	Buy	+10,900	New	+$393K	﹤0.01%	2483

UBS AM's FMTX Position: Q4 2022 in Review

UBS AM sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q4 2022, closing a stake of 18,528 shares — an estimated $370K sold.

UBS AM first reported a position in FMTX in Q1 2021 and held it in 7 quarters. The position peaked at $370K in Q3 2022. 0 funds tracked by Wall St. Rank hold FMTX as of Q4 2022.

UBS AM reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
UBS AM sold 18,528 Forma Therapeutics Holdings, Inc. Common Stock shares in Q4 2022, an estimated $370K.
UBS AM first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
UBS AM's Forma Therapeutics Holdings, Inc. Common Stock position peaked at $370K in Q3 2022.
0 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on UBS AM's 13F filing for Q4 2022, filed 14 Feb 2023.